Abstract
Summary Twenty patients with chronic mucocutaneous candidosis (CMCC) and eleven patients with Candida onychomycosis (CO) were treated with oral ketoconazole. Twenty-seven patients completed therapy after a mean treatment duration of 7-6 months and were both clinically and mycologically free from infection. Clinical and mycological relapse was seen in five CMCC and one CO patient during follow up post treatment (8-4 months mean). All the patients with CMCC who relapsed after ketoconazole presented with recurrent oral candidosis. During treatment, side effects such as nausea, headache and dizziness were seen in seven patients. The mean blood level of the drug i h after 200 mg of ketoconazole was 2–2 mg/1, although some patients showed persistently low levels, below 0-4 mg/1. The use of ketoconazole is a significant advance in the management of chronic Candida infections of the nails. The relapse rate is low and there is a prompt response to retreatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
